ClinicalTrials.gg
CompletedNCT06869018Updated Mar 20, 2026

A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants

A Phase 1 interventional study of LY3549492 and Placebo in Healthy and Type 2 Diabetes Mellitus (T2D), sponsored by Eli Lilly and Company. Completed at 4 sites in Japan. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company — 10 open to participants now, 21 under way, 11 of them phase 3. Diabetes Mellitus, Type 2 · Eli Lilly and Company.

Enrollment
147th of 232
92 · median 181
Started
2025
with 14 others
Phase 1
76 of 238
2 open now
Registered
217th of 238
by date

Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 147th largest by enrollment of the 232 interventional ones that give a count, is one of 15 that started in 2025, is one of 76 in phase 1, and was the 217th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

10 of the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate how well LY3549492 is tolerated and what side effects may occur in Japanese participants with Type 2 Diabetes Mellitus (T2D) and healthy Japanese participants. The study drug will be administered orally. Blood tests will be performed to check how much LY3549492 gets into the bloodstream and how long it takes the body to eliminate it.

The study will last up to approximately 19 weeks for both Part A (Cohorts 1-3) for multiple-ascending doses (MAD), and Part B (Cohorts 4-5) multiple-ascending doses (MAD), for a total of approximately 25 weeks, including screening.

03

Conditions studied

  • Healthy
  • Type 2 Diabetes Mellitus (T2D)

Keywords

  • Glucose Metabolism Disorders
  • Metabolic Diseases
  • Endocrine System Diseases
  • Diabetes Mellitus
  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A:

  • Participants with T2DM for at least 6 months
  • With an value:

    • equal to or greater than 7.0% and equal to or less than 10.0% at screening for participants treated with diet and exercise alone, OR
    • equal to or greater than 6.5% and equal to or less than 9.0% for participants prior to washout of antidiabetic medications
  • Have had a stable weight for the 3 months prior to screening. Stable weight is defined as less than 5% body weight change

Part B:

  • Have safety laboratory test results within normal reference range for the population or investigative site, or results with acceptable deviations that are judged to be not by the investigator. Laboratory tests may be repeated if there is a documented technical error, or once at the discretion of the investigator for any out-of-range results

Exclusion criteria

Exclusion Criteria:

  • Have a known gastric emptying abnormality
  • Have a 12-lead (ECG) abnormality
  • Have an abnormal blood pressure or pulse rate
  • Have a significant history within the past 6 months or current evidence of comorbidities capable of altering the absorption, metabolism, or elimination of drug. Or constituting a risk when taking the study drug
  • Have a history of chronic medical conditions involving the heart, liver, or kidneys
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    LY3549492 Part A

    LY3549492 administered orally

    Drug: LY3549492

  • Experimental
    LY3549492 Part B

    LY3549492 administered orally

    Drug: LY3549492

  • Placebo comparator
    Placebo Part A

    Placebo administered orally

    Drug: Placebo

  • Placebo comparator
    Placebo Part B

    Placebo administered orally

    Drug: Placebo

Interventions

  • Administered orally

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Day 1 Through Day 127

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3549492

    PK: AUC of LY3549492

    Time frame: Day 1 Through Day 127

  2. PK: Maximum Concentration (Cmax) of LY3549492

    PK: Cmax of LY3549492

    Time frame: Day 1 Through Day 127

  3. Pharmacodynamic (PD): Part A: Change from Baseline in Hemoglobin A1c (HbA1c)

    PD: Change from Baseline in Hemoglobin A1c (HbA1c)

    Time frame: Day 1 Through Day 127

  4. PD: Change from Baseline in Body Weight

    PD: Change from Baseline in Body Weight

    Time frame: Day 1 Through Day 127

07

Study locations

4 sites
  • Hakata Clinic
    Fukuoka, 812-0025, Japan
  • P-One Clinic
    Hachiōji, 192-0071, Japan
  • Medical Corporation Heishinkai OPHAC Hospital
    Osaka, 532-0003, Japan
  • Clinical Research Hospital Tokyo
    Shinjuku-ku, 160-0004, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Mar 2026, 9 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 9 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2025
First posted
Mar 11, 2025
StartActual
May 7, 2025
Primary completionActual
Mar 2, 2026
CompletionActual
Mar 2, 2026
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06869018
Responsible party
Sponsor
First posted
Mar 11, 2025
Start date
May 7, 2025
Primary completion
Mar 2, 2026
Completion
Mar 2, 2026
Last update
Mar 20, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naperiglipron

Start the discussion